Curia
Curia Global, commonly referred to as Curia, is a leading contract research, development, and manufacturing organisation headquartered in the United States. Established in 2019, Curia has rapidly expanded its operational footprint across North America and Europe, positioning itself as a key player in the pharmaceutical and biotechnology sectors. Specialising in drug development and manufacturing, Curia offers a comprehensive suite of services, including analytical testing, formulation development, and commercial manufacturing. What sets Curia apart is its commitment to quality and innovation, ensuring that clients receive tailored solutions that meet stringent regulatory standards. With a strong market presence, Curia has achieved significant milestones, including strategic acquisitions that enhance its capabilities. The company is recognised for its expertise in complex drug modalities, making it a trusted partner for clients seeking to navigate the complexities of drug development.
DitchCarbon Score
How does Curia's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Research Services industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Curia's score of 30 is higher than 89% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Curia's reported carbon emissions
In 2022, Curia Global, headquartered in the United States, reported total carbon emissions of approximately 41,290,410 kg CO2e for Scope 1 and about 46,508,720 kg CO2e for Scope 2. This data reflects their commitment to transparency in emissions reporting, covering both direct and indirect emissions associated with their operations. Curia has set ambitious climate commitments, aiming for net-zero emissions across all scopes by 2050. They are currently committed to the Science Based Targets initiative (SBTi), which underscores their dedication to aligning with global climate goals. This long-term target is part of their broader strategy to mitigate climate impact within the pharmaceuticals, biotechnology, and life sciences sector. As they progress towards these goals, Curia continues to focus on reducing their carbon footprint, demonstrating a proactive approach to sustainability and environmental responsibility.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2021 | 2022 | |
|---|---|---|
| Scope 1 | 41,290,410 | 00,000,000 |
| Scope 2 | 46,508,720 | 00,000,000 |
| Scope 3 | - | - |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Curia is committed to some reduction initiatives we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
